Age‐specific outcomes from the first round of HPV screening in unvaccinated women : observational study from the English cervical screening pilot

Objective

To report detailed age-specific outcomes from the first round of an English pilot studying the implementation of high-risk human papillomavirus (HR-HPV) testing in primary cervical screening.

Design

Observational study with screening in 2013–2016, followed by two early recalls and/or colposcopy until the end of 2019.

Setting

Six NHS laboratory sites.

Population

A total of 1 341 584 women undergoing screening with HR-HPV testing or liquid-based cytology (LBC).

Methods

Early recall tests and colposcopies were recommended, depending on the nature of the screening-detected abnormality.

Main outcome measures

We reported standard screening process indicators, e.g. proportions with an abnormality, including high-grade cervical intraepithelial neoplasia (CIN2+) or cancer, and the positive predictive value (PPV) of colposcopy for CIN2+, by screening test and age group.

Results

Among unvaccinated women screened with HR-HPV testing at age 24–29 years, 26.9% had a positive test and 10.4% were directly referred to colposcopy following cytology triage, with a PPV for CIN2+ of 47%. At 50–64 years of age, these proportions were much lower: 5.3%, 1.2% and 27%, respectively. The proportions of women testing positive for HR-HPV without cytological abnormalities, whose early recall HR-HPV tests returned negative results, were similar across the age spans: 54% at 24–29 years and 55% at 50–64 years. Two-thirds of infections at any age were linked to non-16/18 genotypes. Among women with CIN2, CIN3 or cervical cancer, however, the proportion of non-16/18 infections increased with age. As expected, the detection of abnormalities was lower following screening with LBC.

Conclusions

These data provide a reliable reference for future epidemiological studies, including those concerning the effectiveness of HPV vaccination.